Design and implementation of predictive models based on radiomics to assess response to immunotherapy in non-small-cell lung cancer

  1. M. Corral Bolaños 1
  2. B. Farina 2
  3. A.D. Ramos Guerra 3
  4. C. Palacios Miras 4
  5. G. Gallardo Madueño 5
  6. A. Muñoz-Barrutia 6
  7. G. R. Peces-Barba 7
  8. L. M. Seijo 8
  9. J. Corral 8
  10. I. Gil Bazo 9
  11. M. Dómine Gómez 4
  12. M. J. Ledesma-Carbayo 2
  1. 1 Universidad Politécnica de Madrid, Madrid
  2. 2 Universidad Politécnica de Madrid
    info

    Universidad Politécnica de Madrid

    Madrid, España

    ROR https://ror.org/03n6nwv02

  3. 3 Universidad Politécnica de Madrid & CIBER-BBN, Madrid, Spain
  4. 4 Hospital Universitario Fundación Jiménez Díaz & CIBERES, Madrid, Spain
  5. 5 Universidad de Navarra
    info

    Universidad de Navarra

    Pamplona, España

    ROR https://ror.org/02rxc7m23

  6. 6 Universidad Carlos III de Madrid
    info

    Universidad Carlos III de Madrid

    Madrid, España

    ROR https://ror.org/03ths8210

  7. 7 Fundación Jiménez Díaz
    info

    Fundación Jiménez Díaz

    Madrid, España

    ROR https://ror.org/049nvyb15

  8. 8 Clínica Universidad de Navarra & CIBERES & CIBERONC, Madrid, Spain
  9. 9 Instituto de Investigación Sanitaria de Navarra (IDISNA), Pamplona, Spain
Erakutsi afiliazioak +
Liburua:
XXXVIII Congreso Anual de la Sociedad Española de Ingeniería Biomédica. CASEIB 2020: Libro de actas
  1. Roberto Hornero Sánchez (ed. lit.)
  2. Jesús Poza Crespo (ed. lit.)
  3. Carlos Gómez Peña (ed. lit.)
  4. María García Gadañón (ed. lit.)

Argitaletxea: Grupo de Ingeniería Biomédica ; Universidad de Valladolid

ISBN: 978-84-09-25491-0

Argitalpen urtea: 2020

Orrialdeak: 181-184

Biltzarra: Congreso Anual de la Sociedad Española de Ingeniería Biomédica CASEIB (38. 2020. Valladolid)

Mota: Biltzar ekarpena

DIALNET GOOGLE SCHOLAR

Laburpena

Lung cancer is the leading cause of cancer-related deaths in Europe. Immunotherapy treatments have been proved as the new standard of care for stage III-IV non-small cell lung cancer patients. However, the treatments vary in success, and there is not a reliable biomarker. This retrospective project aimed to develop a predictive model based on radiomics through machine learning or deep learning techniques to assess the response to the treatment, understood as the progression (or not) of the disease. Then, the study was complemented with an analysis of the progression-free survival time and an attempt of association with biological data. We used the basal computed tomography images of the primary tumour lesions from a cohort with 84 patients with IV stage nonsmall- cell lung cancer. The best performance model reached an AUC of 0.80 – 90 % CI [0.62, 0.99]. Our results suggest that the radiomics models may be useful for patient classification

Datuen iturria: Dialnet